EX VIVO FUSED NORMAL ALLOGENEIC HUMAN MYOBLAST WITH AUTOLOGOUS HUMAN MYOBLAST DERIVED FROM DUCHENNE MUSCULAR DYSTROPHY AFFECTED DONOR for Duchenne muscular dystrophy

Inclusion criteria

• {"criterion_text":"- Subject and his legal representative/parent(s)/legal guardian have understood and accepted to participate in the study according to all study procedures by signing the approved informed consent.\n- Boys of age 5 to 18 years old (at the time of screening), diagnosed with DMD confirmed by genetic testing.\n- Subjects must be receiving glucocorticosteroids for a minimum of 6 months prior to the biopsy of muscle tissue.\n- Subjects with progressive, symmetrical proximal muscle weakness of arms and legs.\n- Willingness and ability to comply with scheduled visits, tissue biopsy procedure under anesthesia, drug administration plan, laboratory tests, study restrictions, study procedures, and functional testing adapted to the stage of the disease.\n- Willingness to use acceptable forms of contraception if the subject is sexually active.\n- Patients must be cleared by anesthesiologist for tissue biopsy and DT-DEC01 intraosseous injection procedures which will be performed under anesthesia (local anesthesia / general anesthesia / analgosedation)."}

Exclusion criteria

• {"criterion_text":"- Subject was previously exposed to the IMP, any similar experimental therapy with the use of ATMP or any other cell-based product, gene therapy or translarna / ataluren prior to screening.\n- Any injury or procedure which may impact functional testing. Previous injuries must be fully healed prior to consenting. Prior lower limb fractures must be fully healed and at least 3 months should pass from injury date.\n- Presence or history of other musculoskeletal or neurologic disease or somatic disorder not related to DMD including pulmonary and cardiac disease.\n- History of allergic or anaphylactic reaction to a therapeutic or diagnostic protein or additives of the investigational product.\n- Ongoing chronic use of any agents with an immunomodulating (activating or suppressing) effect, such as, but not limited to, immunosuppressants or drugs related to immunotherapy (e.g. based on antibodies), chemotherapy or similar therapy affecting cell proliferation.\n- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for inclusion into this study.\n- Subject has known history of immune reaction to the administered therapies or history of GvHD.\n- Subjects with known cognitive impairment or behavioral issues that would impede the ability to follow instructions.\n- Subject is positive for human immunodeficiency virus (HIV) 1 or 2, hepatitis B (HBV) or C (HCV*), cytomegalovirus (CMV*), toxoplasmosis* or syphilis at screening visit (V0a). *In case of positive or doubtful result of anti-CMV IgG and anti-Toxo IgG, anti-HCV total the final qualification decision can be made after confirming the negative Nucleic Acid Test (NAT) results in cell culture.\n- Subject has a history of any autoimmune disease.\n- Ongoing participation in any other therapeutic clinical trial.\n- Presence of pre-existing antibodies in the subject’s serum against the donor lymphocytes.\n- Subject has undergone an organ or bone marrow transplantation.\n- Change in systemic corticosteroid therapy (e.g. initiation of treatment; cessation of treatment; change in dose, schedule, or type of steroid) within 3 months prior to administration of the investigational product."}

Primary endpoints

• {"endpoint_text":"- Phase 1: The frequency of the incidence and severity of all adverse events – AEs, SAEs and AESI.\n- Phase 1: Mean changes from the baseline (V0a) recorded in the functional assessments adjusted to the stage of the disease: for ambulatory patients: 6MWT, timed functions of NSAA: supine to rise and 10-meter walk/run, for non-ambulatory patients: PUL 2.0, at month 1 (V4), 3 (V5), 6 (V6), and 12 (V7).\n- Phase 1: Mean changes from the baseline (V0a) in the EMG assessment of MUP duration of the selected muscles of upper and lower extremity in both ambulatory and non-ambulatory patients, at month 3 (V5), 6 (V6), and 12 (V7).\n- Phase 2: The frequency of the incidence and severity of all adverse events – AEs, SAEs and AESI.\n- Phase 2: Mean changes from the baseline (V0a) recorded in the functional assessments adjusted to the stage of the disease: a. for ambulatory patients: 6MWT, timed functions of NSAA: supine to rise and 10-meter walk/run b. for non-ambulatory patients: PUL 2.0 at month 1 (V4), 3 (V5), 6 (V6), and 12 (V7).\n- Phase 2: Mean changes from the baseline in the EMG assessment of MUP duration of the selected muscles of upper and lower extremity in both ambulatory and non-ambulatory patients at month 3, 6 and 12 .","definition_or_measurement_approach":"Safety endpoints: frequency and severity of AEs, SAEs and AESIs (clinical observation). Efficacy endpoints: functional assessments adjusted to disease stage — ambulatory: Six-Minute Walk Test (6MWT) and timed NorthStar Ambulatory Assessment functions (supine to rise, 10-meter walk/run); non-ambulatory: PUL 2.0; EMG assessment of Motor Unit Potential (MUP) duration. Timepoints specified at months 1 (V4), 3 (V5), 6 (V6) and 12 (V7) as per phase and endpoint."}

Secondary endpoints

• {"endpoint_text":"- Phase 2: Mean changes from the baseline (V0a) recorded by functional assessments (adjusted to the stage of the disease): for ambulatory patients: PUL 2.0, assessment of grip strength by dynamometer; for non-ambulatory patients: assessment of grip strength by dynamometer. At month 1 (V4), 3 (V5), 6 (V6), and 12 (V7).\n- Phase 2: Mean changes from the baseline (V0a) in QoL assessed by PODCI at month 1 (V4), 3 (V5), 6 (V6), and 12 (V7).\n- Phase 2: Evaluation of Overall Treatment Effect at month 1 (V4), 3 (V5), 6 (V6), and 12 (V7).","definition_or_measurement_approach":"Functional secondary endpoints: PUL 2.0 and grip strength by dynamometer measured at months 1, 3, 6 and 12. QoL measured by PODCI at months 1, 3, 6 and 12. Overall Treatment Effect (OTE) assessed at months 1, 3, 6 and 12."}

Poland

Earliest CTIS Part Ii Submission Date

14-11-2024

Latest Decision Or Authorization Date

24-04-2026

Processing Time Days

526

Number Of Sites

1

Number Of Participants

20

Primary sponsor

Full Name

Dystrogen Therapeutics Technology Polska Sp. z o.o.

Organisation Type

Pharmaceutical company

Country Of Registered Address

Poland